CERo Therapeutics Holdings, Inc. (CERO)
OTCMKTS · Delayed Price · Currency is USD
0.0110
-0.0005 (-4.35%)
At close: Jul 17, 2026

CERO Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Jun '21
Net Income
-19.92-8.3-7.29-0.67-0
Depreciation & Amortization
0.280.440.46--
Stock-Based Compensation
1.960.930.1--
Other Adjustments
1.41-7.820.4-2.84-
Changes in Accounts Payable
2.270.261.281.640
Changes in Accrued Expenses
-0.412.290.04--
Changes in Income Taxes Payable
---0.52-
Changes in Other Operating Activities
-1.67-0.71-0.780.25-
Operating Cash Flow
-16.08-12.92-5.79-1.090
Purchases of Investments
----0.33-
Proceeds from Sale of Investments
0.5--181.16-
Investing Cash Flow
0.5--180.84-
Short-Term Debt Issued
-0.41---
Short-Term Debt Repaid
--0.4---
Net Short-Term Debt Issued (Repaid)
-0.01---
Long-Term Debt Issued
-0.010.610.65-
Long-Term Debt Repaid
--0.02---
Net Long-Term Debt Issued (Repaid)
--0.010.610.65-
Issuance of Common Stock
9.434.810.01--
Repurchase of Common Stock
----139.35-
Net Common Stock Issued (Repurchased)
9.434.810.01-139.35-
Issuance of Preferred Stock
4.998.92---
Repurchase of Preferred Stock
-0.4----
Net Preferred Stock Issued (Repurchased)
4.598.92---
Other Financing Activities
-0.11--0.04--
Financing Cash Flow
13.9213.730.57-138.7-
Net Cash Flow
-1.660.81-5.2241.040
Free Cash Flow
-16.08-12.92-5.79-1.090
Free Cash Flow Per Share
-3.80-445.81-19835.50-98.14-
Levered Free Cash Flow
-95.06-8.81-5.682.390
Unlevered Free Cash Flow
-17.99-13.92-6.6747.370